JP2022505146A5 - - Google Patents
Info
- Publication number
- JP2022505146A5 JP2022505146A5 JP2021521085A JP2021521085A JP2022505146A5 JP 2022505146 A5 JP2022505146 A5 JP 2022505146A5 JP 2021521085 A JP2021521085 A JP 2021521085A JP 2021521085 A JP2021521085 A JP 2021521085A JP 2022505146 A5 JP2022505146 A5 JP 2022505146A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024075254A JP2024096347A (ja) | 2018-10-19 | 2024-05-07 | ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748016P | 2018-10-19 | 2018-10-19 | |
| US62/748,016 | 2018-10-19 | ||
| PCT/US2019/057195 WO2020082065A1 (en) | 2018-10-19 | 2019-10-21 | 9(11)-unsaturated neuroactive steroids and their methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024075254A Division JP2024096347A (ja) | 2018-10-19 | 2024-05-07 | ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505146A JP2022505146A (ja) | 2022-01-14 |
| JP2022505146A5 true JP2022505146A5 (https=) | 2022-10-31 |
| JP7534291B2 JP7534291B2 (ja) | 2024-08-14 |
Family
ID=68468867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521085A Active JP7534291B2 (ja) | 2018-10-19 | 2019-10-21 | ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法 |
| JP2024075254A Pending JP2024096347A (ja) | 2018-10-19 | 2024-05-07 | ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024075254A Pending JP2024096347A (ja) | 2018-10-19 | 2024-05-07 | ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20210363175A1 (https=) |
| EP (2) | EP3867261B1 (https=) |
| JP (2) | JP7534291B2 (https=) |
| CN (1) | CN113227114B (https=) |
| AR (1) | AR116771A1 (https=) |
| AU (2) | AU2019359899B2 (https=) |
| BR (1) | BR112021007401A2 (https=) |
| CA (1) | CA3116892A1 (https=) |
| DK (1) | DK3867261T3 (https=) |
| ES (1) | ES3039267T3 (https=) |
| MX (2) | MX2021004452A (https=) |
| TW (1) | TW202027754A (https=) |
| WO (1) | WO2020082065A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3953429A (en) * | 1970-12-17 | 1976-04-27 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstance and pregnane series |
| DE2526373C2 (de) * | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
| EP0221705A1 (en) * | 1985-10-23 | 1987-05-13 | The Upjohn Company | Tetrahydro angiostatic steroids |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| CN117024501A (zh) * | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
-
2019
- 2019-10-21 ES ES19798489T patent/ES3039267T3/es active Active
- 2019-10-21 WO PCT/US2019/057195 patent/WO2020082065A1/en not_active Ceased
- 2019-10-21 EP EP19798489.1A patent/EP3867261B1/en active Active
- 2019-10-21 TW TW108137951A patent/TW202027754A/zh unknown
- 2019-10-21 JP JP2021521085A patent/JP7534291B2/ja active Active
- 2019-10-21 AU AU2019359899A patent/AU2019359899B2/en active Active
- 2019-10-21 AR ARP190102988A patent/AR116771A1/es unknown
- 2019-10-21 US US17/286,524 patent/US20210363175A1/en not_active Abandoned
- 2019-10-21 CA CA3116892A patent/CA3116892A1/en active Pending
- 2019-10-21 CN CN201980083218.9A patent/CN113227114B/zh active Active
- 2019-10-21 BR BR112021007401-5A patent/BR112021007401A2/pt unknown
- 2019-10-21 MX MX2021004452A patent/MX2021004452A/es unknown
- 2019-10-21 EP EP25172672.5A patent/EP4606812A3/en active Pending
- 2019-10-21 DK DK19798489.1T patent/DK3867261T3/da active
-
2021
- 2021-04-16 MX MX2024014845A patent/MX2024014845A/es unknown
-
2024
- 2024-05-07 JP JP2024075254A patent/JP2024096347A/ja active Pending
- 2024-09-30 AU AU2024220209A patent/AU2024220209A1/en active Pending
- 2024-11-07 US US18/940,062 patent/US20250136638A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022505146A5 (https=) | ||
| CN101400655B (zh) | 喹诺酮衍生物或其制药学可接受的盐 | |
| CN103619824B (zh) | 酰胺化合物及其药物用途 | |
| JP2013542937A5 (https=) | ||
| JP2022514385A5 (https=) | ||
| JP5870112B2 (ja) | 呼吸器合胞体ウイルス感染を治療するための化合物 | |
| JP2022510683A5 (https=) | ||
| JP2022504607A5 (https=) | ||
| JP2023515620A5 (https=) | ||
| JP2013518050A5 (https=) | ||
| AU2014306451B2 (en) | Substituted hydroxamic acid compounds | |
| JP2015520729A5 (https=) | ||
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| CA2840627A1 (en) | Quinazolines as therapeutic compounds and related methods of use | |
| JP2012502067A5 (https=) | ||
| JP2017515844A5 (https=) | ||
| JP2009538910A5 (https=) | ||
| JP2023520924A5 (https=) | ||
| JP2009507909A5 (https=) | ||
| JP2020520955A5 (https=) | ||
| JP2005509003A5 (https=) | ||
| JP2017518323A5 (https=) | ||
| CN103717571B8 (zh) | 9‑氨基甲基取代的四环素类化合物 | |
| JP2012526131A5 (https=) | ||
| JP2010533636A5 (https=) |